nce a bubble starts, a convincing narrative gains traction and the narrative becomes self-reinforcing. As George Soros observed, fundamental analysis seeks to establish how underlying values are reflected in stock prices, whereas the theory of reflexivity shows how stock prices can influence underlying values. For example, in the 1920s people believed that technology like refrigerators, cars, planes, and the radio would change the world (and they did!). In the 1990s, it was the Internet. One of the keys to any bubble is usually loose credit and lending. To finance all the new consumer goods, in the 1920s installment lending was widely adopted, allowing people to buy more than they would have previously. In the 1990s, Internet companies resorted to vendor financing with cheap money that financial markets were throwing at Internet companies. In the housing boom in the 2000s, rising house prices and looser credit allowed more and more people access to credit. And a new financial innovation called securitization developed in the 1990s as a good way to allocate risk and share good returns was perversely twisted into making subprime mortgages acceptable as safe AAA investments.
The successful completion of an efficacy study in an experimental Ebola virus disease model in non-human primates represents an important next step towards understanding the potential of BCX4430 as a treatment for Ebola disease in humans. NIAID, part of the National Institutes of Health, granted a contract to BioCryst in September 2013 valued up to $22.0 million over five years. With this additional award, the BCX4430 development contract has been increased in value to $24.4 million, if all options are exercised.
This project will be funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN272201300017C
NIAID is supporting the development of potential treatments is BCX4430, a drug that BioCryst Pharmaceuticals .
The lead BSAV compound is BCX4430, an RNA dependent-RNA polymerase inhibitor that has demonstrated broad-spectrum activity against more than 20 RNA viruses in nine different families, including filoviruses, togaviruses, bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses and flaviviruses.
BCRX is developing BCX4430 in collaboration with U.S. Government Agencies following the Animal Rule regulatory pathway.
BCRX designs, optimizes and develops novel small molecule drugs that block key enzymes involved in rare diseases.
NLNK fails and TKMR fails left with No choice but BCRX... atleast established a year ago that it works...
“because we’re going to need more than one drug to make sure, because the virus is adapting to us as we’re adapting to it. It mutates into different forms.”
Besides, we all have different DNA, and therefore different ways of reacting to certain drugs. Some drugs that work on one person may not work on another, and vice versa.
“…we’re going to need every single Ebola drug that we have to try to help these patients.”
“That means we’re going to need every single Ebola drug that we have to try to help these patients,” Paul goes on. “And then pray that they work.”
CEO is Garbage+Comedian = Every Lies he speaks he adds YOU KNOW !!!!!!!! Nobody knows only he knows and FDA knows he is bluffing....LOL
Can Stendra save the day?
VIVUS's erectile dysfunction drug, Stendra, was approved by the FDA nearly two years ago. And despite licensing the drug to stronger marketing partners like Auxilium Pharmaceuticals, (NASDAQ: AUXL ) , the drug hasn't made much of an impact on VIVUS's bottom line so far. In the first half of this year, for instance, VIVUS booked only $23.5 million in milestone and licensing revenue from Stendra.
On the bright side, VIVUS and Auxilium recently announced that the FDA approved Stendra's label expansion application, allowing the drug to be taken only 15 minutes before sex. This could help Stendra gain market share against entrenched blockbusters like Viagra and Cialis. That being said, the jury is still out on whether Stendra can turn the tide for VIVUS
Stendra alone can lift VVUS to $10
Breaking ...BUZZ-Orexigen Therapeutics Inc: Diet drug is now officially launched by Takeda with 900 Sales forces..........EMA approval on 24th October
Orexigen Therapeutics Inc. (NASDAQ: OREX) is down a stunning 33% in the past month. The company received approval for its obesity drug Contrave on September 11, and they will be partnering with Takeda Pharmaceutical to launch sales in the coming weeks. While other company’s obesity drugs have had disappointing sales figures, the Merrill Lynch analysts feel that Takeda’s big 900 sales rep force could be a difference maker.
Merrill Lynch has a $9 price target on Orexigen, and the consensus target is even higher at $11. The stock closed on Friday at $4.08.
Past studies have suggested Viagra and other PDE5 inhibitors may have benefits for heart failure by decreasing pulmonary artery resistance and providing cardio-protective effects in settings with low blood flow, according to Kociol.
“They also improve exercise tolerance in patients with heart failure,” he said. The drug may even reduce the size of a heart attack.
Auxilium Pharma recorded Stendra U.S. net revenues of $11.6 million .
Stendra is a highly efficacious ... For the second quarter 2014, "total net revenue was $21.9
Third QTR .............$45?...DOUBLING PATTERN
Now, Auxilium is leaning on one of Stendra's selling points: Its speed. According to its official FDA label, men should take the drug half an hour before they want to get busy. That could give it an edge on well-known older treatments: Eli Lilly's ($LLY) Cialis is taken daily, while Pfizer ($PFE) advises men to take Viagra one to two hours before sex.